In your article on CBD, you mentioned concerns with contraindications of medications that utilize the CYP450 enzymes. How does this affect your recommendation of CBD in practice? It rarely seems to prevent additional pharmaceuticals.

Yes. Basically, from what I’ve seen in the research and also what we’ve seen working with patients, and what I’ve learned in talking to some physicians who are using CBD extensively in their practice and also other pain meds like [for] people with chronic pain practices, generally that inhibition doesn’t really become significant until you’re getting up into the 75- to 100-mg dose range for CBD, and that’s a lot more than most people take. The typical doses of 5 to 25 mg [are what] most patients are taking. We don’t tend to see that, but it’s still something that you should make them and their prescribing physician, if you’re not the prescribing physician of the other medication, aware of just for informed consent and ​CYA​. But, like I said, it’s not something that generally happens at that level. The other thing is that it can actually be useful if it’s done intentionally. There are certain medications [for which] increasing the half-life of them is not necessarily a bad thing. You take a lower dose, you get a bigger effect, and you save money, and [there] may be some side effects, so just keep that in mind as well.